OBJECTIVES: To review outcomes for patients who received intraoperative radiotherapy (IORT) for upper-extremity sarcoma. METHODS: We identified patients with upper-extremity tumors who were treated with external beam radiotherapy, surgery, and IORT, with or without chemotherapy. Kaplan-Meier estimates for overall survival (OS), central control (CC), local control (LC), and distant control (DC) were obtained. RESULTS: Sixty-one patients were identified. Median age was 50 years (range, 13 to 95 y). Median follow-up was 5.9 years. Eleven patients had gross (R2; n=1) or microscopic (R1; n=10) disease at the time of IORT. IORT doses ranged from 7.50 to 20.00 Gy. External beam radiotherapy doses ranged from 19.80 to 54.00 Gy. OS at 5 and 10 years was 72% and 58%, respectively. LC at 5 and 10 years was 91% and 88%, respectively. DC at 5 and 10 years was 80% and 77%, respectively. Patients treated for recurrent disease had inferior 5-year OS compared with patients with first diagnoses (63% vs. 74%; P=0.02) and lower 5-year LC (67% vs. 94%; P<0.01). For patients with R1 or R2 resections, LC at 5 and 10 years was 100% and 86%, respectively; for patients with R0 resections, LC was 89% at both 5 and 10 years (P=0.98). Severe toxicity attributable to treatment was noted for 4 patients (7%). CONCLUSIONS: For upper-extremity sarcoma, treatment including IORT was associated with excellent LC, limb preservation, and survival. LC rates were excellent for patients with positive margins after resection. Patients with recurrent disease had worse outcomes, but limb preservation was achievable for most patients.
OBJECTIVES: To review outcomes for patients who received intraoperative radiotherapy (IORT) for upper-extremity sarcoma. METHODS: We identified patients with upper-extremity tumors who were treated with external beam radiotherapy, surgery, and IORT, with or without chemotherapy. Kaplan-Meier estimates for overall survival (OS), central control (CC), local control (LC), and distant control (DC) were obtained. RESULTS: Sixty-one patients were identified. Median age was 50 years (range, 13 to 95 y). Median follow-up was 5.9 years. Eleven patients had gross (R2; n=1) or microscopic (R1; n=10) disease at the time of IORT. IORT doses ranged from 7.50 to 20.00 Gy. External beam radiotherapy doses ranged from 19.80 to 54.00 Gy. OS at 5 and 10 years was 72% and 58%, respectively. LC at 5 and 10 years was 91% and 88%, respectively. DC at 5 and 10 years was 80% and 77%, respectively. Patients treated for recurrent disease had inferior 5-year OS compared with patients with first diagnoses (63% vs. 74%; P=0.02) and lower 5-year LC (67% vs. 94%; P<0.01). For patients with R1 or R2 resections, LC at 5 and 10 years was 100% and 86%, respectively; for patients with R0 resections, LC was 89% at both 5 and 10 years (P=0.98). Severe toxicity attributable to treatment was noted for 4 patients (7%). CONCLUSIONS: For upper-extremity sarcoma, treatment including IORT was associated with excellent LC, limb preservation, and survival. LC rates were excellent for patients with positive margins after resection. Patients with recurrent disease had worse outcomes, but limb preservation was achievable for most patients.
Authors: Esther Carbó-Laso; Pablo Sanz-Ruiz; José Antonio Calvo-Haro; Miguel Cuervo-Dehesa; Rubén Pérez-Mañanes; Lydia Mediavilla-Santos; Coral Sánchez-Pérez; Ana Álvarez-González; Javier Vaquero-Martín Journal: Int J Clin Oncol Date: 2017-07-17 Impact factor: 3.402
Authors: C V Sole; F A Calvo; M Cambeiro; A Polo; A Montero; R Hernanz; C Gonzalez; M Cuervo; D Perez; M S Julian; R Martinez-Monge Journal: Clin Transl Oncol Date: 2014-01-31 Impact factor: 3.405
Authors: Felipe A Calvo; Claudio V Sole; Alfredo Polo; Mauricio Cambeiro; Angel Montero; Ana Alvarez; Miguel Cuervo; Mikel San Julian; Rafael Martinez-Monge Journal: Strahlenther Onkol Date: 2014-04-09 Impact factor: 3.621
Authors: Fien Hoefkens; Charlotte Dehandschutter; Johan Somville; Paul Meijnders; Dirk Van Gestel Journal: Radiat Oncol Date: 2016-10-12 Impact factor: 3.481
Authors: Christopher L Tinkle; Vivian Weinberg; Steve E Braunstein; Rosanna Wustrack; Andrew Horvai; Thierry Jahan; Richard J O'Donnell; Alexander R Gottschalk Journal: Sarcoma Date: 2015-08-09
Authors: Gustavo R Sarria; Vera Petrova; Frederik Wenz; Yasser Abo-Madyan; Elena Sperk; Frank A Giordano Journal: Radiat Oncol Date: 2020-05-14 Impact factor: 3.481